Sec. 106. FDA OPIOID ACTION PLAN
484 words·~2 min read·
/statute-compilations/comps-12178/sec-106A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
## SEC. 106 FDA OPIOID ACTION PLAN **[**[21 U.S.C. 355 note](/us/usc/t21/s355)**]** ###
(a)In general ####
(1)New drug application #####
(A)In general Subject to subparagraph (B), prior to the approval pursuant to an application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) of a new drug that is an opioid, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall refer the application to an advisory committee of the Food and Drug Administration to seek recommendations from such advisory committee. #####
(B)Public health exemption A referral to an advisory committee under subparagraph
(A)is not required with respect to a new opioid drug or drugs if the Secretary— ######
(i)finds that such a referral is not in the interest of protecting and promoting public health; ######
(ii)finds that such a referral is not necessary based on a review of the relevant scientific information; and ######
(iii)submits a notice containing the rationale for such findings to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives. ####
(2)Pediatric opioid labeling The Secretary shall convene the Pediatric Advisory Committee of the Food and Drug Administration to seek recommendations from such Committee regarding a framework for the inclusion of information in the labeling of drugs that are opioids relating to the use of such drugs in pediatric populations before the Secretary approves any labeling or change to labeling for any drug that is an opioid intended for use in a pediatric population. ####
(3)Sunset The requirements of paragraphs
(1)and
(2)shall cease to be effective on October 1, 2022. ###
(b)Prescriber Education **[**[21 U.S.C. 355-1 note](/us/usc/t21/s355-1)**]** Not later than 1 year after the date of the enactment of this Act, the Secretary, acting through the Commissioner of Food and Drugs, as part of the Food and Drug Administration’s evaluation of the Extended-Release/Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, and in consultation with relevant stakeholders, shall develop recommendations regarding education programs for prescribers of opioids pursuant to section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1), including recommendations on— ####
(1)which prescribers should participate in such programs; and ####
(2)how often participation in such programs is necessary. ###
(c)Guidance on Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products **[**[21 U.S.C. 355 note](/us/usc/t21/s355)**]** Not later than 18 months after the end of the period for public comment on the draft guidance entitled “General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products” issued by the Center for Drug Evaluation and Research of the Food and Drug Administration in March 2016, the Commissioner of Food and Drugs shall publish in the Federal Register a final version of such guidance.
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources